Reshape Lifesciences Inc (OTCMKTS:RSLS) major shareholder Armistice Capital Master Fund acquired 2,523 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was bought at an average cost of $5.45 per share, for a total transaction of $13,750.35. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Tuesday, September 17th, Armistice Capital Master Fund acquired 396,072 shares of Reshape Lifesciences stock. The stock was bought at an average cost of $0.05 per share, for a total transaction of $19,803.60.

OTCMKTS RSLS opened at $5.55 on Friday. The stock’s 50-day moving average price is $1.47 and its 200-day moving average price is $0.44. The company has a quick ratio of 1.07, a current ratio of 1.17 and a debt-to-equity ratio of 0.05. Reshape Lifesciences Inc has a 52 week low of $2.91 and a 52 week high of $70.80.

Reshape Lifesciences Company Profile

ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.

Featured Article: What is Cost of Goods Sold (COGS)?

Insider Buying and Selling by Quarter for Reshape Lifesciences (OTCMKTS:RSLS)

Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.